biOasis Technologies Inc.
TSX VENTURE : BTI
OTCQX : BIOAF

biOasis Technologies Inc.

May 27, 2015 09:00 ET

biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 27, 2015) - biOasis (TSX VENTURE:BTI)(OTCQX:BIOAF) today announces that it, in partnership with the National Research Council of Canada and the Université de Sherbrooke, has been awarded a collaborative research grant by the CQDM and Brain Canada. In their "Focus on Brain" call for proposals, the partners received a number of applications from companies and academic institutions. The focus of the research agreement is to identify a new generation of potential blood-brain barrier (BBB) carrier molecules.

Mr. Rob Hutchison, Principal Investigator, will lead the three teams located at; the National Research Council of Canada (NRC), Dr. Danica Stanimirovic MD, PhD; the Université de Sherbrooke, Dr. Brigitte Guérin; and the biOasis research team. The research funding, as announced by CQDM, $2,573,875 over 3 years, comes from CQDM and Brain Canada, with co-investment (in-kind) from NRC. The primary goal of the project is to develop a platform of blood-brain carriers and evaluate them preclinically. The foundational work will be conducted at NRC, beginning with the isolation of lead blood-brain barrier carriers from an NRC library of human single domain antibodies. Together with the Université de Sherbrooke and biOasis, the research teams will validate potential candidates using in vivo imaging and will conduct comparative studies against known carriers such as biOasis's Transcend.

The project team brings together leaders in the fields of domain antibody engineering (NRC), blood-brain barrier R&D (biOasis, NRC) and in vivo translational imaging (Université de Sherbrooke). The overall project goal is to transfer new brain delivery technology to biOasis for commercial development through licensing agreements with major pharmaceutical companies.

Mr. Rob Hutchison, the CEO of biOasis, commented, "When we became aware of the Focus on Brain program launched by CQDM in partnership with Brain Canada and the Ontario Brain Institute, it was clear to us that biOasis needed to be a part of it, as our central mandate is focused on the delivery of therapeutics to the brain. We've successfully developed our Transcend technology with this goal in mind and now this new collaboration with expert partners represents a wonderful opportunity to expand our BBB carrier platform. Our expert team that developed Transcend will play a significant role in this project, which will enhance our current Transcend offering by expanding the BBB transports that we will be able to provide to our future partners."

About Transcend

Transcend is biOasis' proprietary platform for the delivery of therapeutics across the BBB to address unmet medical needs in the treatment of central nervous system diseases such as; metastatic and other forms of brain cancers, neurodegenerative and metabolic diseases. The BBB represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely breech the BBB offers the opportunity for biOasis to deliver therapeutics into the brain. Transcend was originally based on MTf (melanotransferrin or P97) where the full-length protein was conjugated to therapeutic molecules. Recently biOasis identified a family of peptides within MTf that facilitates receptor mediated transcytosis.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"

Contact Information

  • biOasis Technologies Inc.
    Corporate: Mr. Rob Hutchison 1-778-383-3280
    Scientific: Dr. Reinhard Gabathuler 1 (514) 963-6177
    info@bioasis.ca